In particular, in situ administration of CXCL9 and CXCL10 was used to recruit T cells through the CXCR3 receptor2, which is rapidly expressed by CD8+ T cells following priming in the setting of infection with intracellular pathogens15. Here, CXCL10 is linked to infection.